197 related articles for article (PubMed ID: 20458652)
41. Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
del Giglio A; Weinschenker P; Manhani AR; Carbonell AL; Mitteldorf CA
South Med J; 2005 Feb; 98(2):238-40. PubMed ID: 15759959
[TBL] [Abstract][Full Text] [Related]
42. Pomalidomide in the treatment of relapsed multiple myeloma.
Forsberg PA; Mark TM
Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
[TBL] [Abstract][Full Text] [Related]
43. Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland.
Freimann H; Calderoni A; Cornu P; Olie R
Swiss Med Wkly; 2007 Jun; 137(21-22):317-22. PubMed ID: 17629810
[TBL] [Abstract][Full Text] [Related]
44. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
45. Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
Cavo M
Leukemia; 2006 Aug; 20(8):1341-52. PubMed ID: 16810203
[TBL] [Abstract][Full Text] [Related]
46. [Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].
Huang WR; Li R; Jing Y; Zhang YZ; Wu XX; Gao CJ; Bo J; Yu L; Wang QS; Da WM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1146-50. PubMed ID: 17204182
[TBL] [Abstract][Full Text] [Related]
47. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
Richardson P; Jagannath S; Colson K
Clin Adv Hematol Oncol; 2006 May; 4(5):1; discussion 8; suppl 13. PubMed ID: 16830422
[TBL] [Abstract][Full Text] [Related]
48. Clinical management of myeloma--state of the art.
Harousseau JL
Cancer Treat Rev; 2010 May; 36 Suppl 2():S1-2. PubMed ID: 20472182
[TBL] [Abstract][Full Text] [Related]
49. [Multiple myeloma -- therapy].
Jung W; Zettl F; Schroers R
Dtsch Med Wochenschr; 2005 Feb; 130(6):283-6; quiz 287-90. PubMed ID: 15692903
[No Abstract] [Full Text] [Related]
50. Current therapy of myeloma induced renal failure.
Gertz MA
Leuk Lymphoma; 2008 May; 49(5):833-4. PubMed ID: 18452070
[No Abstract] [Full Text] [Related]
51. Management of older patients with multiple myeloma.
Gay F; Palumbo A
Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
[TBL] [Abstract][Full Text] [Related]
52. Genomic stratification of multiple myeloma treated with novel agents.
Jiang A; Reece D; Chang H
Leuk Lymphoma; 2012 Feb; 53(2):202-7. PubMed ID: 21823830
[TBL] [Abstract][Full Text] [Related]
53. Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma.
Minarik J; Scudla V; Bacovsky J; Zemanova M; Pika T; Ordeltova M; Langova K
Neoplasma; 2010; 57(1):8-14. PubMed ID: 19895166
[TBL] [Abstract][Full Text] [Related]
54. Brain abscess caused by Nocardia cyriacigeorgica in two patients with multiple myeloma: novel agents, new spectrum of infections.
Pamukçuoğlu M; Emmez H; Tunçcan OG; Oner AY; Cırak MY; Senol E; Sucak GT
Hematology; 2014 Apr; 19(3):158-62. PubMed ID: 23906027
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Möller J; Nicklasson L; Murthy A
J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
[TBL] [Abstract][Full Text] [Related]
56. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
57. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
[TBL] [Abstract][Full Text] [Related]
58. HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Ria R; Catacchio I; Berardi S; De Luisi A; Caivano A; Piccoli C; Ruggieri V; Frassanito MA; Ribatti D; Nico B; Annese T; Ruggieri S; Guarini A; Minoia C; Ditonno P; Angelucci E; Derudas D; Moschetta M; Dammacco F; Vacca A
Clin Cancer Res; 2014 Feb; 20(4):847-58. PubMed ID: 24297864
[TBL] [Abstract][Full Text] [Related]
59. Investigational treatments for multiple myeloma.
Bringhen S; Avonto I; Magarotto V; Boccadoro M; Palumbo A
Expert Opin Investig Drugs; 2006 Dec; 15(12):1565-82. PubMed ID: 17107282
[TBL] [Abstract][Full Text] [Related]
60. Expanding role of bortezomib in multiple myeloma: nursing implications.
Colson K; Doss DS; Swift R; Tariman J
Cancer Nurs; 2008; 31(3):239-49. PubMed ID: 18453881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]